These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16990635)

  • 1. Adverse-drug-event rates for high-cost and high-use drugs in the intensive care unit.
    Kane-Gill S; Rea RS; Verrico MM; Weber RJ
    Am J Health Syst Pharm; 2006 Oct; 63(19):1876-81. PubMed ID: 16990635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of intravenous adverse drug events in academic and nonacademic intensive care units.
    Nuckols TK; Paddock SM; Bower AG; Rothschild JM; Fairbanks RJ; Carlson B; Panzer RJ; Hilborne LH
    Med Care; 2008 Jan; 46(1):17-24. PubMed ID: 18162851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.
    Bates DW; Spell N; Cullen DJ; Burdick E; Laird N; Petersen LA; Small SD; Sweitzer BJ; Leape LL
    JAMA; 1997 Jan 22-29; 277(4):307-11. PubMed ID: 9002493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a computer-based adverse-drug-event monitor.
    Hwang SH; Lee S; Koo HK; Kim Y
    Am J Health Syst Pharm; 2008 Dec; 65(23):2265-72. PubMed ID: 19020194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug events in an intensive care unit of a university hospital.
    Reis AM; Cassiani SH
    Eur J Clin Pharmacol; 2011 Jun; 67(6):625-32. PubMed ID: 21246350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational study of adult admissions to a medical ICU due to adverse drug events.
    Jolivot PA; Pichereau C; Hindlet P; Hejblum G; Bigé N; Maury E; Guidet B; Fernandez C
    Ann Intensive Care; 2016 Dec; 6(1):9. PubMed ID: 26830112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving adverse drug event detection in critically ill patients through screening intensive care unit transfer summaries.
    Anthes AM; Harinstein LM; Smithburger PL; Seybert AL; Kane-Gill SL
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):510-6. PubMed ID: 23440931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of adverse drug events in an academic hospital: a prospective cohort study.
    Aljadhey H; Mahmoud MA; Mayet A; Alshaikh M; Ahmed Y; Murray MD; Bates DW
    Int J Qual Health Care; 2013 Dec; 25(6):648-55. PubMed ID: 24141014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computerized surveillance of adverse drug events in hospital patients.
    Classen DC; Pestotnik SL; Evans RS; Burke JP
    JAMA; 1991 Nov; 266(20):2847-51. PubMed ID: 1942452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for hospital admissions associated with adverse drug events.
    Kongkaew C; Hann M; Mandal J; Williams SD; Metcalfe D; Noyce PR; Ashcroft DM
    Pharmacotherapy; 2013 Aug; 33(8):827-37. PubMed ID: 23686895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug event nonrecognition in emergency departments: an exploratory study on factors related to patients and drugs.
    Roulet L; Ballereau F; Hardouin JB; Chiffoleau A; Potel G; Asseray N
    J Emerg Med; 2014 Jun; 46(6):857-64. PubMed ID: 24565882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency department visits caused by adverse drug events: results of a French survey.
    Queneau P; Bannwarth B; Carpentier F; Guliana JM; Bouget J; Trombert B; Leverve X; Lapostolle F; Borron SW; Adnet F;
    Drug Saf; 2007; 30(1):81-8. PubMed ID: 17194173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a computerized drug-monitoring program to detect and prevent adverse drug events and medication non-adherence in outpatient ambulatory care: study protocol of a randomized controlled trial.
    Forster AJ; Erlanger TE; Jennings A; Auger C; Buckeridge D; van Walraven C; Tamblyn R
    Trials; 2015 Jan; 16():2. PubMed ID: 25572800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of adult admissions to ICUs related to adverse drug events.
    Jolivot PA; Hindlet P; Pichereau C; Fernandez C; Maury E; Guidet B; Hejblum G
    Crit Care; 2014 Nov; 18(6):643. PubMed ID: 25529263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical approach to determining costs and frequency of adverse drug events in a health care network.
    Senst BL; Achusim LE; Genest RP; Cosentino LA; Ford CC; Little JA; Raybon SJ; Bates DW
    Am J Health Syst Pharm; 2001 Jun; 58(12):1126-32. PubMed ID: 11449856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of adverse drug events on morbidity and mortality in intensive care units: the JADE study.
    Ohta Y; Sakuma M; Koike K; Bates DW; Morimoto T
    Int J Qual Health Care; 2014 Dec; 26(6):573-8. PubMed ID: 25192926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of expanded use of clinical pharmacist practitioners in addition to team-based care in a community health system intensive care unit.
    Michalets E; Creger J; Shillinglaw WR
    Am J Health Syst Pharm; 2015 Jan; 72(1):47-53. PubMed ID: 25511838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug event reporting in intensive care units: a survey of current practices.
    Kane-Gill SL; Devlin JW
    Ann Pharmacother; 2006; 40(7-8):1267-73. PubMed ID: 16849619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The costs of adverse drug events in community hospitals.
    Hug BL; Keohane C; Seger DL; Yoon C; Bates DW
    Jt Comm J Qual Patient Saf; 2012 Mar; 38(3):120-6. PubMed ID: 22435229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost of adverse drug events in ambulatory care.
    Burton MM; Hope C; Murray MD; Hui S; Overhage JM
    AMIA Annu Symp Proc; 2007 Oct; ():90-3. PubMed ID: 18693804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.